Abstract
The pathogenesis of segmental colitis associated with diverticula (SCAD) is unclear, but tumour necrosis factor alpha (TNF-α) has been shown to play a pivotal role in the pathogenesis of inflammatory bowel diseases. The aim of this study was to assess TNF-α levels in patients with SCAD. In a post hoc analysis of a prospective multicenter study, tissue samples from 13 patients diagnosed with SCAD were subjected to histological analyses. The severity of the inflammation was assessed by means of a histological score and histomorphometry (number of inflammatory cells/mm2). Immunohistochemical staining with an antibody against TNF-α was performed on all biopsies and the degree of staining expressed as the percentage of positive stromal cells/1000 counted (TNF-α score). Matched patients with irritable bowel syndrome (IBS) were used as controls. Over-expression of TNF-α was found in all SCAD patients (38.6 ± 10.4%), and it was associated with a high histological score (2.5 ± 0.5) and neutrophil cell count (16.3 ± 3/mm2). These values were distinctly higher than those found in the IBS controls. Our data suggest that TNF-α activity is involved in SCAD pathogenesis, similarly to what occurs in Crohn’s disease and ulcerative colitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hughes LE (1969) Post-mortem survey of diverticular disease of the colon. 1. Diverticulosis and diverticulitis. Gut 10:336–344
Imperiali G, Meucci G, Alvisi C et al (2000) Segmental colitis associated with diverticula: a prospective study. Am J Gastroenterol 95:1014–1016
Koutroubakis IE, Antoniou P, Tzardi M et al (2005) The spectrum of segmental colitis associated with diverticulosis. Int J Colorectal Dis 20:28–32
Gledhill A, Dixon MF (1998) Crohn’s-like reaction in diverticular disease. Gut 42:392–395
Shepherd NA (1996) Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Gut 38:801–802
Peppercorn MA (1992) Drug-responsive chronic segmental colitis associated with diverticula: a clinical syndrome in the elderly. Am J Gastroenterol 87:609–612
Reimund JM, Wittersheim C, Dumont S et al (1996) Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 39:684–689
Murch SH, Lamkin VA, Savage MO et al (1991) Serum concentrations of tumour necrosis factor a in childhood chronic inflammatory bowel disease. Gut 32:913–917
Braegger CP, Nicholls S, Murch SH et al (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89–91
Reinecker H-C, Steffen M, Witthoeft T et al (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1b by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 94:174–181
Plevy SE, Landers CJ, Prehn J et al (1997) A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 159:6276–6282
Berner B, Akca D, Jung T et al (2000) Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 27:1128–1135
Murch SH, Braegger CP, Walker-Smith JA et al (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705–1709
Hassan C, Ierardi E, Burattini O et al (2007) tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 39:811–817
Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF-antibody. Mol Immunol 30:1443–1453
Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476
Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549
Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulising Crohn’s disease. N Engl J Med 350:876–885
Baert FJ, D’Haens GR, Peeters M et al (1999) tumour necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28
Hassan C, Zullo A, Ierardi E et al (2006) Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula. Gut 55:589–590
Imperiali G, Terpin MM, Meucci G et al (2006) Segmental colitis associated with diverticula: a 7-year follow-up study. Endoscopy 38:610–612
Morson BC, Dawson IMP (1979) Gastro-intestinal pathology, 2nd edn. Blackwell Scientific Publications, Oxford, pp 530–533
Ierardi E, Monno RA, Gentile A et al (2001) Helicobacter heilmannii gastritis: a histological and immunohistochemical trait. J Clin Pathol 54:774–777
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ierardi, E., Meucci, G., Hassan, C. et al. Tumour Necrosis Factor Alpha in Segmental Colitis Associated with Diverticula . Dig Dis Sci 53, 1865–1868 (2008). https://doi.org/10.1007/s10620-007-0086-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-007-0086-9